CA2691346A1 - Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells - Google Patents
Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells Download PDFInfo
- Publication number
- CA2691346A1 CA2691346A1 CA2691346A CA2691346A CA2691346A1 CA 2691346 A1 CA2691346 A1 CA 2691346A1 CA 2691346 A CA2691346 A CA 2691346A CA 2691346 A CA2691346 A CA 2691346A CA 2691346 A1 CA2691346 A1 CA 2691346A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cancer
- carcinoma
- cell
- dendritic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 199
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 115
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 107
- 201000011510 cancer Diseases 0.000 title claims abstract description 83
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims description 29
- 108010047761 Interferon-alpha Proteins 0.000 title claims description 8
- 102000006992 Interferon-alpha Human genes 0.000 title claims description 8
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title claims 11
- 239000000427 antigen Substances 0.000 claims abstract description 97
- 102000036639 antigens Human genes 0.000 claims abstract description 96
- 108091007433 antigens Proteins 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 201000001441 melanoma Diseases 0.000 claims description 92
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 82
- 229960005486 vaccine Drugs 0.000 claims description 43
- 210000001616 monocyte Anatomy 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 21
- 238000011068 loading method Methods 0.000 claims description 19
- 230000006044 T cell activation Effects 0.000 claims description 18
- 230000001939 inductive effect Effects 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 208000009956 adenocarcinoma Diseases 0.000 claims description 12
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- 230000002147 killing effect Effects 0.000 claims description 11
- 230000004069 differentiation Effects 0.000 claims description 8
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 201000003076 Angiosarcoma Diseases 0.000 claims description 6
- 206010003571 Astrocytoma Diseases 0.000 claims description 6
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 6
- 201000009047 Chordoma Diseases 0.000 claims description 6
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 6
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 6
- 206010014967 Ependymoma Diseases 0.000 claims description 6
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 6
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 6
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 208000007054 Medullary Carcinoma Diseases 0.000 claims description 6
- 208000000172 Medulloblastoma Diseases 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000007641 Pinealoma Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 201000000582 Retinoblastoma Diseases 0.000 claims description 6
- 201000010208 Seminoma Diseases 0.000 claims description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 6
- 208000008383 Wilms tumor Diseases 0.000 claims description 6
- 208000004064 acoustic neuroma Diseases 0.000 claims description 6
- 230000001640 apoptogenic effect Effects 0.000 claims description 6
- 201000007180 bile duct carcinoma Diseases 0.000 claims description 6
- 201000001531 bladder carcinoma Diseases 0.000 claims description 6
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 6
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 6
- 208000037828 epithelial carcinoma Diseases 0.000 claims description 6
- 201000002222 hemangioblastoma Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 206010024627 liposarcoma Diseases 0.000 claims description 6
- 201000005296 lung carcinoma Diseases 0.000 claims description 6
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 claims description 6
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 6
- 206010027191 meningioma Diseases 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 208000001611 myxosarcoma Diseases 0.000 claims description 6
- 208000025189 neoplasm of testis Diseases 0.000 claims description 6
- 201000008968 osteosarcoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 6
- 201000010198 papillary carcinoma Diseases 0.000 claims description 6
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 6
- 201000004123 pineal gland cancer Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 6
- 230000035939 shock Effects 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 201000010965 sweat gland carcinoma Diseases 0.000 claims description 6
- 206010042863 synovial sarcoma Diseases 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 6
- 230000030741 antigen processing and presentation Effects 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 3
- 101100129915 Escherichia coli (strain K12) melB gene Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 claims 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 description 24
- 108090000695 Cytokines Proteins 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 230000008569 process Effects 0.000 description 22
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 21
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 17
- 238000010200 validation analysis Methods 0.000 description 17
- 229940029030 dendritic cell vaccine Drugs 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 229920005557 bromobutyl Polymers 0.000 description 14
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 12
- 230000000735 allogeneic effect Effects 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 12
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 11
- 230000008014 freezing Effects 0.000 description 11
- 238000007710 freezing Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 230000035899 viability Effects 0.000 description 11
- 108010002586 Interleukin-7 Proteins 0.000 description 9
- 102000000704 Interleukin-7 Human genes 0.000 description 9
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 208000021039 metastatic melanoma Diseases 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 8
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000002617 apheresis Methods 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 6
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 6
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 6
- 206010020843 Hyperthermia Diseases 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108010029697 CD40 Ligand Proteins 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 5
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036031 hyperthermia Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 102000002227 Interferon Type I Human genes 0.000 description 4
- 108010014726 Interferon Type I Proteins 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000012808 vapor phase Substances 0.000 description 4
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 3
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 3
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 3
- 101100326920 Caenorhabditis elegans ctl-1 gene Proteins 0.000 description 3
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 229920000392 Zymosan Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000012737 microarray-based gene expression Methods 0.000 description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 2
- 102100039328 Endoplasmin Human genes 0.000 description 2
- 101150031823 HSP70 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000812663 Homo sapiens Endoplasmin Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 101150052825 dnaK gene Proteins 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011027 product recovery Methods 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 description 1
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 description 1
- 229940035785 IFN-DC vaccine Drugs 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100028748 Transportin-1 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229940099550 actimmune Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYXYTGQFPZEUFX-UHFFFAOYSA-N benzpyrimoxan Chemical compound O1C(OCCC1)C=1C(=NC=NC=1)OCC1=CC=C(C=C1)C(F)(F)F ZYXYTGQFPZEUFX-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81791606P | 2006-06-30 | 2006-06-30 | |
| US60/817,916 | 2006-06-30 | ||
| PCT/US2007/072525 WO2008005859A2 (en) | 2006-06-30 | 2007-06-29 | Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2691346A1 true CA2691346A1 (en) | 2008-01-10 |
Family
ID=38895372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2691346A Abandoned CA2691346A1 (en) | 2006-06-30 | 2007-06-29 | Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080031900A1 (enExample) |
| EP (2) | EP2037957A4 (enExample) |
| JP (3) | JP2009542714A (enExample) |
| KR (1) | KR20090033375A (enExample) |
| CN (1) | CN101511384A (enExample) |
| AU (1) | AU2007269245B2 (enExample) |
| CA (1) | CA2691346A1 (enExample) |
| WO (1) | WO2008005859A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009149382A2 (en) * | 2008-06-06 | 2009-12-10 | Baylor Research Institute | Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells |
| US8728465B2 (en) * | 2008-06-17 | 2014-05-20 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
| JP2013522309A (ja) * | 2010-03-15 | 2013-06-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 活性化した成熟樹状細胞を調製し保存するシステムおよび方法 |
| KR20140054140A (ko) * | 2011-07-27 | 2014-05-08 | 베일러 리서치 인스티튜트 | 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법 |
| SG11201401631VA (en) * | 2011-10-20 | 2014-05-29 | California Stem Cell Inc | Antigen presenting cancer vaccine with gamma interferon |
| EP2591798B1 (en) | 2011-11-09 | 2014-11-19 | Werner Lubitz | Vaccine for use in tumor immunotherapy |
| CN112646778A (zh) * | 2012-12-28 | 2021-04-13 | 阿姆弗拉公司 | 免疫原性裂解物制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及药物组合物 |
| EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
| JP6967963B2 (ja) * | 2014-07-17 | 2021-11-17 | ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. | 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法 |
| SG11201701728PA (en) * | 2014-09-04 | 2017-04-27 | Agency Science Tech & Res | A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells |
| WO2016064899A1 (en) * | 2014-10-21 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy |
| WO2016148179A1 (ja) * | 2015-03-17 | 2016-09-22 | 国立大学法人信州大学 | Ｉｆｎを用いた非接着培養による樹状細胞の調製方法 |
| JP7019578B2 (ja) * | 2015-12-30 | 2022-02-15 | セルジーン コーポレイション | Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球 |
| EP3195878A1 (en) | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| CN108567977B (zh) * | 2017-03-13 | 2022-04-12 | 复旦大学 | 一种免疫增强剂、免疫治疗药物组合物及其制备与用途 |
| KR20190057938A (ko) | 2017-11-21 | 2019-05-29 | 이근량 | 버스닥트의 다점 온도감지 및 광학적 경보시스템 |
| CA3087418A1 (en) * | 2018-01-18 | 2019-07-25 | University Of South Florida | Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases |
| WO2019204391A1 (en) * | 2018-04-19 | 2019-10-24 | Robert Caruso | Cryo-inactivated cancer cells for cancer immunotherapy |
| WO2020180648A1 (en) * | 2019-03-01 | 2020-09-10 | Gritstone Oncology, Inc. | Selection of t cell receptors |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| JP7859015B2 (ja) * | 2021-07-15 | 2026-05-15 | 大日本印刷株式会社 | 細胞医薬品の提供方法 |
| KR20250110348A (ko) | 2022-11-23 | 2025-07-18 | 제이제이알앤디 엘엘씨 | 암 세포독성 엑소좀 제형 및 암 치료에 사용되는 방법 |
| WO2024256477A1 (en) * | 2023-06-13 | 2024-12-19 | Pdc Line Pharma Sa | Method for preparing plasmacytoid dendritic cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT633929E (pt) * | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| US6821778B1 (en) | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
| DE69839215T2 (de) | 1997-04-15 | 2009-03-19 | Dana-Farber Cancer Institute, Inc., Boston | Dendritische zellhybride |
| CA2318557A1 (en) * | 1998-01-16 | 1999-07-22 | Biomira Usa Inc. | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
| WO1999042564A2 (en) | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| US7015205B1 (en) * | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
| DE10041515A1 (de) * | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| CA2542686A1 (en) * | 2003-10-15 | 2005-05-06 | Istituto Superiore Di Sanita | Colorectal cancer antigen |
| US20050214268A1 (en) * | 2004-03-25 | 2005-09-29 | Cavanagh William A Iii | Methods for treating tumors and cancerous tissues |
| US20060045883A1 (en) * | 2004-08-26 | 2006-03-02 | Jeffrey Molldrem | Anti-cancer vaccines |
| CN101052709B (zh) * | 2004-10-25 | 2012-06-27 | 贝勒研究院 | 装载热激黑素瘤细胞体的树突细胞 |
-
2007
- 2007-06-29 CN CNA200780032430XA patent/CN101511384A/zh active Pending
- 2007-06-29 KR KR1020097002075A patent/KR20090033375A/ko not_active Abandoned
- 2007-06-29 US US11/771,664 patent/US20080031900A1/en not_active Abandoned
- 2007-06-29 JP JP2009518581A patent/JP2009542714A/ja active Pending
- 2007-06-29 CA CA2691346A patent/CA2691346A1/en not_active Abandoned
- 2007-06-29 EP EP07812497A patent/EP2037957A4/en not_active Withdrawn
- 2007-06-29 WO PCT/US2007/072525 patent/WO2008005859A2/en not_active Ceased
- 2007-06-29 AU AU2007269245A patent/AU2007269245B2/en not_active Ceased
- 2007-06-29 EP EP13159462.4A patent/EP2630968A1/en not_active Withdrawn
-
2013
- 2013-05-28 JP JP2013111446A patent/JP2013177430A/ja active Pending
-
2015
- 2015-10-22 JP JP2015207617A patent/JP6134763B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007269245A1 (en) | 2008-01-10 |
| KR20090033375A (ko) | 2009-04-02 |
| EP2630968A1 (en) | 2013-08-28 |
| EP2037957A2 (en) | 2009-03-25 |
| JP2009542714A (ja) | 2009-12-03 |
| JP2016041725A (ja) | 2016-03-31 |
| CN101511384A (zh) | 2009-08-19 |
| EP2037957A4 (en) | 2010-09-08 |
| JP2013177430A (ja) | 2013-09-09 |
| WO2008005859A2 (en) | 2008-01-10 |
| WO2008005859A3 (en) | 2008-11-20 |
| AU2007269245B2 (en) | 2012-04-12 |
| JP6134763B2 (ja) | 2017-05-24 |
| US20080031900A1 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007269245B2 (en) | Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells | |
| Hao et al. | Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes | |
| Reardon et al. | The development of dendritic cell vaccine-based immunotherapies for glioblastoma | |
| US20080171023A1 (en) | Method to increase class i presentation of exogenous antigens by human dendritic cells | |
| US20080112962A1 (en) | Dendritic Cells Loaded with Heat Shocked Melanoma Cell Bodies | |
| CN102933228A (zh) | 制备和储存活化的、成熟树突细胞的体系和方法 | |
| AU2001259760A1 (en) | Method to increase class I presentation of exogenous antigens by human dendritic cells | |
| Quah et al. | The application of dendritic cell-derived exosomes in tumour immunotherapy | |
| Wang et al. | Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes | |
| Sanchez et al. | T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas | |
| JP2003512335A (ja) | メラノーマワクチン並びにその製造方法及び使用方法 | |
| Rojas Salas et al. | Dendritic cells vaccines: Immunotherapy against cancer | |
| Paglia et al. | Presentation of tumor antigens: The role of dendritic cells | |
| HK1161977B (en) | Method to increase class i presentation of exogenous antigens by human dendritic cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20160629 |